Luvometinib
Small molecule
Evidence outlook
Approved: Pediatric patients 2 years and older with Langerhans cell histiocytosis (LCH) after... (CN)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also in development:Non-Small Cell Lung Cancer · Phase 2 · investigational in the US
Also approved (2)
- Pediatric patients 2 years and older with Langerhans cell histiocytosis (LCH) after systemic therapy
- Adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms; pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN) not amenable to complete resection
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07004075 NCT07004075 · Low-grade Glioma Registry: NCT07004075 | 3 | Compare the progression free survival (PFS) of FCN-159 versus chemotherapy by IRC (up to 48 months) 2027-04-30 | In progress: results expected 30 Apr 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other MEK1/2 drugs
Binimetinib, Cobimetinib, Trametinib. Compare all 4 MEK1/2 drugs
3 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Glioma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Luvometinib: this drug | Phase 3 | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Cobimetinib | Approved(overall) | Small molecule | MEK1/2 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Dabrafenib | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | not yet graded | No reviewed efficacy summary in this indication | |
| Dordaviprone | Approved | Small molecule | Mitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | Partial signal | NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results). | |
| Tovorafenib | Approved | Small molecule | Kinase Inhibitor | Weak signal | No reviewed efficacy summary in this indication | |
| Trametinib | Approved | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Safusidenib | Phase 3 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Abemaciclib (Verzenio) | Phase 2 | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Olutasidenib | Phase 2 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Vebreltinib | Phase 1 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Luvometinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.